The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, China.
Department of Orthopedics, The Affiliated Hospital of Qingdao University, Qingdao, China.
Front Immunol. 2024 Aug 5;15:1444452. doi: 10.3389/fimmu.2024.1444452. eCollection 2024.
Adjuvant therapy is essential in cancer treatment to enhance primary treatment effectiveness, reduce adverse effects, and prevent recurrence. Small molecule inhibitors as adjuvants in cancer immunotherapy aim to harness their immunomodulatory properties to optimize treatment outcomes. By modulating the tumor microenvironment, enhancing immune cell function, and increasing tumor sensitivity to immunotherapy, small molecule inhibitors have the potential to improve patient responses. This review discusses the evolving use of small molecule inhibitors as adjuvants in cancer treatment, highlighting their role in enhancing the efficacy of immunotherapy and the opportunities for advancing cancer therapies in the future.
辅助治疗在癌症治疗中至关重要，可增强主要治疗效果、降低不良反应并预防复发。小分子抑制剂作为癌症免疫治疗的辅助药物，旨在利用其免疫调节特性来优化治疗效果。通过调节肿瘤微环境、增强免疫细胞功能以及提高肿瘤对免疫治疗的敏感性，小分子抑制剂有可能改善患者的反应。本综述讨论了小分子抑制剂作为癌症治疗辅助药物的应用进展，强调了它们在增强免疫治疗疗效方面的作用，并探讨了未来推进癌症治疗的机会。
